Welcome to the Longest Standing Industry Focused Meeting Delivering an End-to-End Overview of This Highly Competitive & Dynamic Landscape.
As the radiopharmaceuticals field shows continued clinical efficacy, increased investment and advances in treatment indication, targeting mechanism, radioisotope and much more- the 6th Targeted Radiopharmaceutical Summit Europe returns as the leading comprehensive forum offering data-driven insights, case study presentations, and informative discussions led by forward thinking radiopharmaceutical pioneers.
Built with the industry’s specific needs in mind, we will address the most pressing challenges and exciting opportunities facing the flourishing radiopharmaceuticals field. Whether you’re working on the discovery and development of novel targets or moiety, bringing new molecules to the clinic or expanding isotope supply chain, advancing clinical expertise in late-stage or approved therapeutics- our end-end meeting has you covered.
Join our community of dedicated radiopharmaceutical developers, ranging from brand-new rising stars to long-standing pioneers of the field. There’s something for everyone at the longest standing industry focused radiopharmaceutical meeting.
What’s in Store?
1
Unearthing novel targets for radiopharmaceuticals from ACP3m, AVB6, AVB8 and PDL-1 with Philochem and TRIMT while revealing cutting-edge targeting moieties for enhanced specificity and efficacy from Starget Pharma and Star Pharma
2
Interrogating isotope comparison data to understand the optimal blend of biological half-life, physical half-life and targeting moiety while exploring immune profiles stimulated with OranoMed and Ariceum
3
Understanding what it really means to be health system ready when implementing radiopharmaceuticals into hospitals with Novartis and influencing health care policy and pricing and reimbursement to expand patient access
4
Turbocharging your manufacturing safety, quality and efficiency exploring novel isolation technologies and new processes with ARTBIO and RadioPharm Theranostics and measuring alphas in the clinic
5
Assessing dosimetry regulatory guidelines and exploring exactly how it should be implemented into the clinic for enhanced patient safety and efficacy with Bayer Lund University, Institute of Cancer Research and more
